News By Tag
News By Place
Cures Within Reach Launches New Impact Awards Program to Support Repurposing Startups
Chicago-based ResQ Pharma, Inc. First Recipient of Impact Award
Unlike its other funding mechanisms for researchers at academic institutions, the Impact Awards are intended for startups that have identified repurposing-
"We developed the Impact Awards to better serve as a value-creating catalyst and facilitator, ultimately driving more treatments to more patients more quickly," said Cures Within Reach President and COO Barbara Goodman. "Our team recognizes that a repurposing startup could be just a single milestone away from moving toward attracting a significant infusion of capital or achieving commercial success. We are eager to help de-risk repurposing startups."
Inaugural Impact Award Presented to Chicago Startup ResQ Pharma
Cures Within Reach selected ResQ Pharma, Inc., to receive its first Impact Award – a $50,000 award for the company to conduct a two-part safety study. ResQ is a biopharmaceutical company focused on ensuring reliable global access to LipidRescue™
During pre-NDA (New Drug Application)
"Based on the growing interest in non-opioid drug overdoses, our team, including the inventor, Guy Weinberg, MD, decided to launch LRT with an improved formulation instead of the version currently used off label by clinicians,"
Burton said the company anticipates receiving FDA approval for the LAST indication in mid-2019, adding words of appreciation for the support of repurposing startups through the Impact Awards. "We are thrilled that Cures Within Reach recognizes the work that we are doing can quickly impact patients, and are excited about its support for companies like ours," Paul said. "It is sometimes difficult to get investors to pay attention to repurposing in general, and supporting incremental improvements in science is even more challenging. We believe that our two-phase safety study will generate data that will lead to the commercialization of our life-saving LRT product."
About Cures Within Reach
Cures Within Reach (CWR) is a US-based global philanthropic leader that improves patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly. CWR catalyzes research to facilitate and validate repurposing opportunities that create clinical impact, and enables and facilitates conversation and action among stakeholders that help transform healthcare through repurposing opportunities. Through repurposing, CWR drives both market impact and health savings to patients and patient groups, from academia / researchers, with payers and the healthcare industry and with support from the government, philanthropy and others. CWR's repurposing research projects have generated over a dozen "new" treatments making patient impact through off-label use in clinical practice or through a commercialization track.
CWR currently has a global portfolio of 20 repurposing research projects, either funded or approved for funding, as well as more than 180 repurposing research projects available for funding in a wide range of diseases on its CureAccelerator® site. Visit cureswithinreach.org (http://www.cureswithinreach.org) or follow CWR via Twitter @CuresWReach, LinkedIn (LinkedIn.com/
About ResQ Pharma
ResQ Pharma, Inc., is a biopharmaceutical company created by Guy Weinberg, MD to ensure reliable, global access to LRT as a treatment for various lipophilic drug overdoses and poisonings. It is already the opinion of the American Heart Association and American College of Medical Toxicology that where there is serious hemodynamic instability from local anesthetic drugs with high lipid solubility, LRT is a reasonable consideration for therapy, even if the patient is not in cardiac arrest. It is a member of iBIO's PROPEL, EnterpriseWorks Chicago, The BUNKER and MATTER, and is also a Qualified New Business Venture for the Illinois Investment Tax Credit Program. For more information, please visit www.ResQPharma.com.